In re: Anagnostou et al. Serial No.: 09/525,808 Filed: March 15, 2000

Page 2 of 5

Listing of Claims

The following list of claims will replace all prior versions and listings of claims in the application.

1-15. (Canceled)

16. (Currently Amended) A method of treating endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

wherein said endothelial injury is caused by mechanical damage, exposure to radiation, inflammation[,] or heart disease or cancer.

17. (Original) A method according to claim 16, wherein said endothelial injury is caused by mechanical damage.

18. (Canceled

- 19. (Original) A method according to claim 16, wherein said endothelial injury is caused by inflammation.
- 20. (Original) A method according to claim 16, wherein said endothelial injury is caused by heart disease.
 - 21. (Canceled)
- 22. (Currently Amended) A method according to claim 16, wherein said erythropoietin is administered intraveneously intravenously.

23-30. (Canceled)

31. (Currently Amended) A method of treating endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

In re: Anagnostou et al. Serial No.: 09/525,808

Filed: March 15, 2000

Page 3 of 5

wherein said effective endothelial-protecting amount of erythropoietin reduces or prevents the suppression of endothelial growth associated with endothelial injury caused by mechanical damage, exposure to radiation, exposure to cisplatin, inflammation [[,] or heart disease or cancer.

32. (Currently Amended) A method of treating endothelial injury in a subject, comprising administering an effective endothelial-protecting amount of erythropoietin to said subject in need of such treatment,

wherein said effective endothelial-protecting amount of erythropoietin increases the numbers of viable endothelial cells following endothelial injury caused by mechanical damage, exposure to radiation, exposure to cisplatin, inflammation [[,] or heart disease or cancer.

33. (Previously Presented) A method according to claim 16, wherein said erythropoietin is administered in an amount of from about 100 Units per kilogram to about 200 Units per kilogram.

34-39. (Canceled)

40. (Currently Amended) A method according to claim <u>31</u> [[35]], wherein said erythropoietin is administered intraveneously.